Tripep AB changes name to ChronTech Pharma AB
The Annual General Meeting of Tripep AB, held in Stockholm on 10 March 2010, resolved to change the company name to ChronTech Pharma AB, in order to better reflect the company’s business, i.e. to develop therapies for chronic diseases. As from Wednesday March 24, 2010, the company’s share will be traded under the code CTEC on First North. For more information, please contact: Anders Vahlne, CEO and Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail: anders.vahlne@ki.se Tripep develops the therapeutic DNA-vaccines ChronVac-C® and ChronVac-B drugs against